Vera Therapeutics, Inc.
atacicept
IgAN
Countdown
542days
Phase 3 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 3 trial results for atacicept in IgAN are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Pivotal ORIGIN 3 study completion with two-year eGFR data – expected in 2027”